{"id":1526,"date":"2011-04-15T06:28:36","date_gmt":"2011-04-15T10:28:36","guid":{"rendered":"http:\/\/blogs.nejm.org\/?p=1526"},"modified":"2011-04-15T06:28:36","modified_gmt":"2011-04-15T10:28:36","slug":"a-new-antiretroviral-option-quietly-enters-the-market","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/a-new-antiretroviral-option-quietly-enters-the-market\/2011\/04\/15\/","title":{"rendered":"A &#8220;New&#8221; Antiretroviral Option Quietly Enters the Market"},"content":{"rendered":"<p>There&#8217;s a new antiretroviral option out there, <a href=\"http:\/\/www.fda.gov\/ForConsumers\/ByAudience\/ForPatientAdvocates\/HIVandAIDSActivities\/ucm248800.htm\" target=\"_blank\">a 400-mg extended-release tablet formulation of nevirapine<\/a> that can be dosed once daily.<\/p>\n<p>However, you might not have noticed, since it&#8217;s not <em>really <\/em>that new, and it&#8217;s not clear that this formulation offers any significant advantages over the nevirapine we already have. \u00a0Writes Keith Henry over in <a href=\"http:\/\/aids-clinical-care.jwatch.org\/cgi\/content\/full\/2011\/411\/5\" target=\"_blank\"><em>Journal Watch<\/em><\/a>:<\/p>\n<blockquote><p>Issues that will temper enthusiasm for the new formulation include continued concern about serious adverse effects with nevirapine (namely, Stevens-Johnson syndrome in the general patient population, and liver toxicity in women with CD4 counts &gt;250 cells\/mm<sup>3<\/sup> and men with CD4 counts &gt;400 cells\/mm<sup>3<\/sup>), the availability of safe and effective non\u2013nevirapine-containing regimens, the likely approval of additional one-pill once-daily regimens (e.g., tenofovir\/FTC\/rilpivirine, abacavir\/3TC\/dolutegravir, and tenofovir\/FTC\/elvitegravir\/cobicistat), and the possibility of nevirapine coming off patent in 2012 (which creates potential for a lower-priced generic).<\/p><\/blockquote>\n<p>Add to these issues the need to still take* the 200 mg once-daily lead in for 14 days, and one wonders how much use this &#8220;new and improved&#8221; nevirapine is going to get.<\/p>\n<p>(*I know, split infinitive &#8212; it just sounds better that way!)<\/p>\n","protected":false},"excerpt":{"rendered":"<p>There&#8217;s a new antiretroviral option out there, a 400-mg extended-release tablet formulation of nevirapine that can be dosed once daily. However, you might not have noticed, since it&#8217;s not really that new, and it&#8217;s not clear that this formulation offers any significant advantages over the nevirapine we already have. \u00a0Writes Keith Henry over in Journal [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,5,8],"tags":[647],"class_list":["post-1526","post","type-post","status-publish","format-standard","hentry","category-hiv","category-infectious-diseases","category-patient-care","tag-nevirapine"],"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/posts\/1526","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/comments?post=1526"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/posts\/1526\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/media?parent=1526"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/categories?post=1526"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/tags?post=1526"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}